SuperworthVistagen Therapeutics shares outstanding VTGN
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 43M
- On a year earlier
- +34.6%
- more shares
Vistagen Therapeutics had 43M diluted shares outstanding on average in Q1 FY27, the quarter to Jun 30, 2026.
That is 34.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2026 | 42.4M | +34% |
| FY2025 | 31.6M | +3% |
| FY2024 | 30.6M | +529% |
| FY2021 | 4.9M | +210% |
| FY2020 | 1.6M | +34% |
| FY2019 | 1.2M | +53% |
| FY2018 | 762.7K | +166% |
| FY2017 | 286.7K | +305% |
| FY2016 | 70.8K | +45% |
| FY2015 | 48.9K | +26% |
| FY2014 | 38.8K | +15% |
| FY2013 | 33.7K | +22% |
| FY2012 | 27.6K | +215% |
| FY2011 | 8.7K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q1 FY27 | 43M | +35% | |
| Q4 FY26 | 42.4M | +34% | |
| Q3 FY26 | 42.2M | +38% | |
| Q2 FY26 | 35.7M | +17% | |
| Q1 FY26 | 31.9M | +4% | |
| Q4 FY25 | 31.6M | +3% | |
| Q3 FY25 | 30.7M | +5% | |
| Q2 FY25 | 30.6M | +205% | |
| Q1 FY25 | 30.6M | +317% | |
| Q4 FY24 | 30.6M | n/a | |
| Q3 FY24 | 29.4M | n/a | |
| Q2 FY24 | 10M | n/a |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Vistagen Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.